$FATE
Fate Therapeutics Inc Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022014236 Filed on August 03, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$14.98M	$18.55M	$18.41M
YoY Change	5.31%	38.3%	65.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$21.56M	$20.35M	$20.74M
YoY Change	37.14%	67.25%	65.94%
% of Gross Profit
Research & Development	$79.82M	$81.31M	$72.14M
YoY Change	50.23%	69.31%	60.84%
% of Gross Profit
Depreciation & Amortization	$3.193M	$2.962M	$2.761M
YoY Change	110.2%	154.25%	187.9%
% of Gross Profit
Operating Expenses	$101.4M	$101.7M	$92.88M
YoY Change	47.24%	68.89%	61.95%
Operating Profit	-$86.39M	-$83.11M	-$74.47M
YoY Change	58.16%	77.66%	61.15%
Interest Expense	$2.678M	$6.638M	$8.777M
YoY Change	-76.33%	-179.46%	683.66%
% of Operating Profit
Other Income/Expense, Net	$2.828M	$7.004M	$8.777M
YoY Change	-75.01%	-183.84%	682.96%
Pretax Income	-$83.56M	-$76.11M	-$65.69M
YoY Change	92.95%	38.04%	45.69%
Income Tax
% Of Pretax Income
Net Earnings	-$83.56M	-$76.11M	-$65.69M
YoY Change	92.95%	38.04%	45.69%
Net Earnings / Revenue	-557.79%	-410.29%	-356.74%
Basic Earnings Per Share	-$0.86	-$0.79	-$0.68
Diluted Earnings Per Share	-$0.86	-$0.79	-$681.8K
COMMON SHARES
Basic Shares Outstanding	97.00M	96.70M	96.43M
Diluted Shares Outstanding	97.02M	96.70M	96.34M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$505.1M	$568.9M	$573.8M
YoY Change	-25.57%	-18.22%	-27.38%
Cash & Equivalents	$82.09M	$55.28M	$64.74M
Short-Term Investments	$423.0M	$513.6M	$509.0M
Other Short-Term Assets	$19.97M	$17.18M	$11.45M
YoY Change	159.32%	133.15%	59.07%
Inventory
Prepaid Expenses
Receivables	$10.22M	$13.13M	$13.85M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$535.3M	$599.2M	$599.1M
YoY Change	-22.83%	-16.0%	-25.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$109.1M	$103.1M	$97.86M
YoY Change	46.24%	-17.77%	-15.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$13.94M	$11.93M	$67.94M
YoY Change	-88.84%	-92.02%	-30.88%
Other Assets	$33.00K	$33.00K	$33.00K
YoY Change	266.67%	-99.78%	-99.78%
Total Long-Term Assets	$214.0M	$207.9M	$259.3M
YoY Change	-26.42%	-31.25%	7.29%
TOTAL ASSETS
Total Short-Term Assets	$535.3M	$599.2M	$599.1M
Total Long-Term Assets	$214.0M	$207.9M	$259.3M
Total Assets	$749.3M	$807.1M	$858.4M
YoY Change	-23.89%	-20.54%	-17.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.593M	$8.420M	$11.44M
YoY Change	48.98%	45.9%	27.16%
Accrued Expenses	$50.15M	$40.52M	$35.11M
YoY Change	-7.14%	57.46%	67.74%
Deferred Revenue	$35.24M	$33.66M	$22.58M
YoY Change	49.68%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$103.9M	$91.52M	$77.91M
YoY Change	13.12%	-13.34%	-17.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$127.4M	$135.1M	$147.1M
YoY Change	-21.53%	-14.52%	-8.81%
Total Long-Term Liabilities	$127.4M	$135.1M	$147.1M
YoY Change	-21.53%	-14.52%	-8.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$103.9M	$91.52M	$77.91M
Total Long-Term Liabilities	$127.4M	$135.1M	$147.1M
Total Liabilities	$231.3M	$226.6M	$225.0M
YoY Change	-9.0%	-14.04%	-12.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$994.4M	-$910.9M	-$834.8M
YoY Change	41.97%
Common Stock	$97.00K	$97.00K	$97.00K
YoY Change	2.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$518.0M	$580.5M	$633.4M
YoY Change
Total Liabilities & Shareholders Equity	$749.3M	$807.1M	$858.4M
YoY Change	-23.89%	-20.54%	-17.94%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$83.56M	-$76.11M	-$65.69M
YoY Change	92.95%	38.04%	45.69%
Depreciation, Depletion And Amortization	$3.193M	$2.962M	$2.761M
YoY Change	110.2%	154.25%	187.9%
Cash From Operating Activities	-$55.05M	-$53.16M	-$64.61M
YoY Change	64.93%	65.59%	138.46%
INVESTING ACTIVITIES
Capital Expenditures	-$8.676M	-$10.13M	$10.08M
YoY Change	-41.12%	-25.63%	153.3%
Acquisitions
YoY Change
Other Investing Activities	$89.05M	$50.42M	$3.058M
YoY Change	-3.93%	311.56%	-100.65%
Cash From Investing Activities	$80.38M	$40.29M	-$7.026M
YoY Change	3.1%	-3040.66%	-98.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.487M	3.406M	2.797M
YoY Change	-81.28%	-8.42%	-99.36%
NET CHANGE
Cash From Operating Activities	-55.05M	-53.16M	-64.61M
Cash From Investing Activities	80.38M	40.29M	-7.026M
Cash From Financing Activities	1.487M	3.406M	2.797M
Net Change In Cash	26.82M	-9.466M	-68.84M
YoY Change	-48.94%	-68.18%	12.98%
FREE CASH FLOW
Cash From Operating Activities	-$55.05M	-$53.16M	-$64.61M
Capital Expenditures	-$8.676M	-$10.13M	$10.08M
Free Cash Flow	-$46.37M	-$43.03M	-$74.70M
YoY Change	148.77%	132.82%	140.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20213000
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8676000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2021Q2	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
	dei	Entity Central Index Key EntityCentralIndexKey	0001434316
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity File Number EntityFileNumber	001-36076
	dei	Entity Registrant Name EntityRegistrantName	FATE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-1311552
	dei	Entity Address Address Line1 EntityAddressAddressLine1	12278 Scripps Summit Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92131
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	875-1800
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	FATE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97000294
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55275000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133583000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13126000
CY2022Q2	fate	Short Term Investments And Related Maturity Receivables ShortTermInvestmentsAndRelatedMaturityReceivables	513575000
CY2021Q4	fate	Short Term Investments And Related Maturity Receivables ShortTermInvestmentsAndRelatedMaturityReceivables	482327000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17181000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8826000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	599157000
	fate	Fair Value Liabilities Level1 To Level3 Transfers Amount FairValueLiabilitiesLevel1ToLevel3TransfersAmount	0
	us-gaap	Net Income Loss NetIncomeLoss	-141795000
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96862797
CY2021Q4	us-gaap	Assets Current AssetsCurrent	633412000
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	11925000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	100664000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103116000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91529000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68493000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70720000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15227000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15227000
CY2022Q2	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	9108000
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	9870000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33000
CY2022Q2	us-gaap	Assets Assets	807059000
CY2021Q4	us-gaap	Assets Assets	921455000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8420000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8612000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40524000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42412000
CY2022Q2	fate	Cirm Award Liability Current CIRMAwardLiabilityCurrent	3200000
CY2021Q4	fate	Cirm Award Liability Current CIRMAwardLiabilityCurrent	3200000
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	33657000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21483000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5717000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5577000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	91518000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	81284000
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	17743000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	27124000
CY2022Q2	fate	Cirm Award Liability Noncurrent CIRMAwardLiabilityNoncurrent	800000
CY2021Q4	fate	Cirm Award Liability Noncurrent CIRMAwardLiabilityNoncurrent	800000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	106587000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	109241000
CY2022Q2	fate	Stock Price Appreciation Milestones Liabilities Non Current StockPriceAppreciationMilestonesLiabilitiesNonCurrent	9928000
CY2021Q4	fate	Stock Price Appreciation Milestones Liabilities Non Current StockPriceAppreciationMilestonesLiabilitiesNonCurrent	24168000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96862797
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13412000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36963000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95726962
	fate	Fair Value Liabilities Level2 To Level3 Transfers Amount FairValueLiabilitiesLevel2ToLevel3TransfersAmount	0
	us-gaap	Investment Income Interest InvestmentIncomeInterest	723000
CY2022Q2	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-5881000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8354000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95726962
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	97000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1494642000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1448584000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3381000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-762000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-910878000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-769083000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	580483000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	678838000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	807059000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	921455000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18549000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24552000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81307000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48023000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	153446000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92873000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20351000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12168000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41093000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24668000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	101658000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	60191000
	us-gaap	Operating Expenses OperatingExpenses	194539000
	us-gaap	Operating Expenses OperatingExpenses	117541000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-83109000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-46779000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-157576000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-92989000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	757000
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	346000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1175000
CY2021Q2	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	8700000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-14240000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	7956000
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	366000
CY2021Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	366000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7004000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15781000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7233000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-14240000
	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	7956000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4450000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-76105000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55133000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.07
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59202000
	us-gaap	Net Income Loss NetIncomeLoss	-100222000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-531000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	174000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2619000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-156000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-76636000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-54959000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-144414000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-100378000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.47
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96704413
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96704413
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94326648
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94326648
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96524968
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96524968
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93881734
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93881734
	us-gaap	Profit Loss ProfitLoss	-141795000
	us-gaap	Profit Loss ProfitLoss	-100222000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5723000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2125000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39873000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26230000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1398000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2629000
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	763000
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1602000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2793000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5208000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4788000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8136000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1669000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	586000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9550000
	fate	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	-287000
	fate	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	2593000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117772000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-90693000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148810000
CY2021Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	15200000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25100000
	fate	Fair Value Liabilities Level3 To Level2 Transfers Amount FairValueLiabilitiesLevel3ToLevel2TransfersAmount	0
	fate	Fair Value Liabilities Level3 To Level1 Transfers Amount FairValueLiabilitiesLevel3ToLevel1TransfersAmount	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17600000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	196115000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	629244000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	249589000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	173584000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33261000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-473260000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6203000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9323000
	fate	Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	0
	fate	Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	432446000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6203000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	441769000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-78308000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	182574000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70502000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	91881000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1469000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1435000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	518000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1546000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, accrued expenses, stock-based compensation, and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	678000
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	356000
	us-gaap	Variable Lease Cost VariableLeaseCost	1295000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55275000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76654000
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15227000
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15227000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70502000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	91881000
CY2022Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	15200000
	us-gaap	Variable Lease Cost VariableLeaseCost	591000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	4543000
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	3897000
	us-gaap	Operating Lease Cost OperatingLeaseCost	8975000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-76100000
	us-gaap	Net Income Loss NetIncomeLoss	-141800000
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27700000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27700000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55100000
	us-gaap	Net Income Loss NetIncomeLoss	-100200000
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25100000
	fate	Expected Ressarch Services Period ExpectedRessarchServicesPeriod	P4Y
CY2022Q2	fate	Transfer Of Assets From Level1 To Level2 TransferOfAssetsFromLevel1ToLevel2	0
CY2020	fate	Period To Treat Award As Grant If Award Not Treated As Loan PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan	P10Y
CY2021	fate	Investment Maturity Date Range InvestmentMaturityDateRange	1 or les
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	405001000
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3417000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	414126000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	763000
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2022Q2	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2021Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2022Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2021Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2022Q2	us-gaap	Share Price SharePrice	24.78
CY2022Q2	us-gaap	Share Price SharePrice	24.78
	us-gaap	Operating Lease Cost OperatingLeaseCost	7666000
CY2022Q2	fate	Transfer Of Assets From Level2 To Level1 TransferOfAssetsFromLevel2ToLevel1	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	16554000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	18358000
CY2022Q2	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	11684000
CY2021Q4	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	12344000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12286000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11710000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40524000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42412000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y10M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0819
CY2022Q2	fate	Straight Line Lease Expense StraightLineLeaseExpense	3865000
CY2021Q2	fate	Straight Line Lease Expense StraightLineLeaseExpense	3541000
	fate	Straight Line Lease Expense StraightLineLeaseExpense	7680000
	fate	Straight Line Lease Expense StraightLineLeaseExpense	7075000
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	7713000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14498000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14836000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15087000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	15540000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	16006000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	101636000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	185316000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	73012000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	112304000
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	174000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55133000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20542000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13254000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39873000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26230000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	678838000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3001000
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19331000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2088000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-65690000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	633393000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3184000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20542000
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-531000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-76105000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	580483000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	384445000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5648000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12976000
CY2021Q1	fate	Public Offering Of Common Stock And Issuance Of Pre Funded Warrants PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants	432445000
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-330000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-45089000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	790095000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3681000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13254000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	752071000

Files In Submission

Name	View Source	Status
0000950170-22-014236-index-headers.html	Edgar Link	pending
0000950170-22-014236-index.html	Edgar Link	pending
0000950170-22-014236.txt	Edgar Link	pending
0000950170-22-014236-xbrl.zip	Edgar Link	pending
fate-20220630.htm	Edgar Link	pending
fate-20220630.xsd	Edgar Link	pending
fate-20220630_cal.xml	Edgar Link	unprocessable
fate-20220630_def.xml	Edgar Link	unprocessable
fate-20220630_htm.xml	Edgar Link	completed
fate-20220630_lab.xml	Edgar Link	unprocessable
fate-20220630_pre.xml	Edgar Link	unprocessable
fate-ex10_2.htm	Edgar Link	pending
fate-ex31_1.htm	Edgar Link	pending
fate-ex31_2.htm	Edgar Link	pending
fate-ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
Fate Therapeutics Inc Stock $fate

2022 Q3 Form 10-Q Financial Statement

#000095017022014236 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE Fate Therapeutics Inc Stock $fate

2022 Q3 Form 10-Q Financial Statement

#000095017022014236 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
Fate Therapeutics Inc Stock $fate